newsfilter
← Latest News
Business Wire·

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

TTRX
  • Turn Therapeutics completed Stage 1/Phase 2a trial of GX-03 for atopic dermatitis, showing 59.3% of patients achieved clear or almost clear skin after four weeks versus 30.4% for the vehicle group.
  • In the full intent-to-treat population, 40.7% of GX-03 patients achieved EASI-100 (no visible eczema) at Week 8 compared to 17.4% for the vehicle group.
  • Patients with severe itch showed improved results with 61.5% achieving clear or almost clear skin with GX-03 after four weeks compared to 8.3% for the vehicle group.
  • The ongoing Phase 2b atopic dermatitis trial is enrolling 120–136 patients with severe itch; no dropouts have been recorded to date.
  • Topline results for the Phase 2b atopic dermatitis trial are expected in the first quarter of 2027.
  • Turn Therapeutics accelerated the planned Phase 2a trial of GX-03 for hidradenitis suppurativa, with enrollment now expected to begin in the first quarter of 2027.
  • The hidradenitis suppurativa trial will involve approximately 80 patients comparing GX-03 to a placebo to assess safety, efficacy, lesion reduction, and pain relief.
  • Former CDC Director Robert R. Redfield, M.D., was appointed Chief Scientific Officer to guide scientific strategy for GX-03 across multiple indications.
  • GX-03 animal studies published in August 2026 showed a 50% reduction in IL-36 proteins \& a 68% reduction in IL-31 itching protein.
  • Cash and cash equivalents totaled $10.4 million as of September 30, 2026, with operations funded into the third quarter of 2027.
  • General and administrative expenses were $1.4 million for the three months ended September 30, 2026, down from $1.8 million in the prior year period.
  • Research and development expenses increased to $0.6 million for the three months ended September 30, 2026, reflecting continued spending on the Phase 2b atopic dermatitis trial.
  • The net loss for the three months ended September 30, 2026, was $6.2 million, or $0.21 per share, compared to a $1.9 million loss in the same period of 2025.
  • GX-03 is a proprietary, non-systemic topical formulation currently being evaluated for atopic dermatitis, hidradenitis suppurativa, \& onychomycosis.